Search Results - "Jacobson, Mark A."

Refine Results
  1. 1
  2. 2
  3. 3

    Valganciclovir Reduces T Cell Activation in HIV-Infected Individuals With Incomplete CD4⁺ T Cell Recovery on Antiretroviral Therapy by Hunt, Peter W., Martin, Jeffrey N., Sinclair, Elizabeth, Epling, Lorrie, Teague, Juli, Jacobson, Mark A., Tracy, Russell P., Corey, Lawrence, Deeks, Steven G.

    Published in The Journal of infectious diseases (15-05-2011)
    “…Background. Elevated immune activation persists during treated human immunodeficiency virus (HIV) infection and is associated with blunted CD4 recovery and…”
    Get full text
    Journal Article
  4. 4

    Temperature Screening of Healthcare Personnel Is Ineffective in Controlling COVID-19 by Maung, Zaw, Kristensen, Marissa, Hoffman, Bridget, Jacobson, Mark A.

    “…Our aim was to describe the effectiveness of employee temperature screening at a public hospital in San Francisco during the COVID-19 pandemic. An estimated…”
    Get full text
    Journal Article
  5. 5
  6. 6

    Human herpesvirus replication and abnormal CD8+ T cell activation and low CD4+ T cell counts in antiretroviral-suppressed HIV-infected patients by Jacobson, Mark A, Ditmer, Dirk P, Sinclair, Elizabeth, Martin, Jeffrey N, Deeks, Steven G, Hunt, Peter, Mocarski, Edward S, Shiboski, Caroline

    Published in PloS one (17-04-2009)
    “…Most HIV-infected patients receiving virologically suppressive antiretroviral therapy continue to have abnormal, generalized T cell activation. We explored…”
    Get full text
    Journal Article
  7. 7
  8. 8

    Risk of subsequent SARS‐CoV‐2 infection among vaccinated employees with or without hybrid immunity acquired early in the Omicron‐predominant era of the COVID‐19 pandemic by Jacobson, Mark A., Blanc, Paul D., Tulsky, Jacqueline, Tilly, Monica, Meister, Raymond, Huen, Will, McNicholas, James E.

    Published in American journal of industrial medicine (01-04-2024)
    “…Background Hybrid immunity, from COVID‐19 vaccination followed by SARS‐CoV‐2 infection acquired after its Omicron variant began predominating, has provided…”
    Get full text
    Journal Article
  9. 9

    Trafficking of Human Immunodeficiency Virus Type 1-Specific CD8+ T Cells to Gut-Associated Lymphoid Tissue during Chronic Infection by Shacklett, Barbara L, Cox, Catherine A, Sandberg, Johan K, Stollman, Neil H, Jacobson, Mark A, Nixon, Douglas F

    Published in Journal of Virology (01-05-2003)
    “…Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
    Get full text
    Journal Article
  10. 10

    Do CD4+ T cell functional responses to Epstein-Barr virus provide protective immunity against CNS lymphoma in AIDS? by Jacobson, Mark A

    Published in PLoS medicine (01-03-2007)
    “…Jacobson discusses a new study addressing the question of whether an EBV antigen-specific T cell response might be a critical component of protective immunity…”
    Get full text
    Journal Article
  11. 11

    A Rapid Nucleic Acid Amplification Test–Based, Conditional Release-to-Work Policy for Health Care Personnel With Symptoms Consistent With COVID-19 by Jacobson, Mark A., Hart, Colin, Huen, Will, Suarez Guardado, Griselda, Villanueva, Allyson, Whitman, Jeffrey, Blanc, Paul D.

    “…Most health care personnel (HCP) reporting symptoms consistent with COVID-19 illness are assessed by high-accuracy SARS-CoV-2 assays performed in clinical…”
    Get full text
    Journal Article
  12. 12

    Human papillomavirus infection in the oral cavity of HIV patients is not reduced by initiating antiretroviral therapy by Shiboski, Caroline H, Lee, Anthony, Chen, Huichao, Webster-Cyriaque, Jennifer, Seaman, Todd, Landovitz, Raphael J, John, Malcolm, Reilly, Nancy, Naini, Linda, Palefsky, Joel, Jacobson, Mark A

    Published in AIDS (London) (19-06-2016)
    “…OBJECTIVE:The incidence of human papillomavirus (HPV)-related oral malignancies is increasing among HIV-infected populations, and the prevalence of oral warts…”
    Get full text
    Journal Article
  13. 13

    Phase 1 Trial of a Single Dose of Recombinant Human Interleukin-12 in Human Immunodeficiency Virus-Infected Patients with 100-500 CD4 Cells/μL by Jacobson, Mark A., Hardy, David, Connick, Elizabeth, Watson, Jessica, DeBruin, Michael

    Published in The Journal of infectious diseases (01-10-2000)
    “…A phase 1 dose-escalation trial of a single subcutaneous dose of recombinant human (rh) interleukin (IL)-12 was conducted in medically stable human…”
    Get full text
    Journal Article
  14. 14
  15. 15
  16. 16

    Regulatory T Cells and the Risk of CMV End-Organ Disease in Patients With AIDS by Weinberg, Adriana, Bosch, Ronald, Bennett, Kara, Tovar-Salazar, Adriana, Benson, Constance A, Collier, Ann C, Zolopa, Andrew, Gulick, Roy M, Wohl, David, Polsky, Bruce, Erice, Alejo, Jacobson, Mark A

    “…OBJECTIVES:Cytomegalovirus (CMV)-specific T-cell effectors (CMV-Teff) protect against CMV end-organ disease (EOD). In HIV-infected individuals, their numbers…”
    Get full text
    Journal Article
  17. 17

    Development of Cytomegalovirus (CMV) Immune Recovery Uveitis Is Associated with Th17 Cell Depletion and Poor Systemic CMV-Specific T Cell Responses by Hartigan-O'Connor, Dennis J., Jacobson, Mark A., Tan, Qi Xuan, Sinclair, Elizabeth

    Published in Clinical infectious diseases (01-02-2011)
    “…Background. The immune reconstitution inflammatory syndromes (IRIS) are a spectrum of inflammatory conditions associated with opportunistic infections and…”
    Get full text
    Journal Article
  18. 18

    A CMV DNA vaccine primes for memory immune responses to live-attenuated CMV (Towne strain) by Jacobson, Mark A, Adler, Stuart P, Sinclair, Elizabeth, Black, Douglas, Smith, Anna, Chu, Alice, Moss, Ron B, Wloch, Mary K

    Published in Vaccine (04-03-2009)
    “…Abstract CMV-seronegative subjects vaccinated intramuscularly or intradermally with a DNA vaccine encoding pp65, IE1, and gB were administered live-attenuated…”
    Get full text
    Journal Article
  19. 19
  20. 20